Drug Trial Radar · NCT07472517
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
670
Planned (sponsor's estimate)
Start
Apr 13, 2026
Primary completion
Sep 9, 2028
Study completion Jul 30, 2029
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Mar 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker DLL3. Participants are put into 2 groups randomly, which means by chance. One group receives obrixtamig and standard treatment. The other group receives standard treatment without obrixtamig. All treatments are given as infusions into a vein. Participants are in the study for up to 3 years. During this time, they visit the study site regularly. Participants in the group receiving obrixtamig stay overnight at the study site following the first 2 obrixtamig treatments. At the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Small Cell Lung Cancer (SCLC)
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Interventions
obrixtamigDrug
obrixtamig
atezolizumabDrug
atezolizumab
carboplatinDrug
carboplatin
etoposideDrug
etoposide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Up to 36 months
Locations
242 sites in 42 countries. Site status is shown where the registry gives one.
Infirmary Cancer Care
Mobile, Alabama · Not yet recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Not yet recruiting
Bioresearch Partner - Hialeah Hospital
Hialeah, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Norton Cancer Institute, Downtown
Louisville, Kentucky · Recruiting
Pikeville Medical Center
Pikeville, Kentucky · Not yet recruiting
Epic Medical Research - Monroe
Monroe, Louisiana · Recruiting
Epic Medical Research - Shreveport
Shreveport, Louisiana · Recruiting
University of Maryland School of Medicine
Baltimore, Maryland · Recruiting
Veterans Affairs Ann Arbor Healthcare System
Ann Arbor, Michigan · Not yet recruiting
HCA MidAmerica Division, Inc.
Kansas City, Missouri · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
Cape Fear Valley Cancer Center
Fayetteville, North Carolina · Recruiting
AHN Cancer Institute - Allegheny General
Pittsburgh, Pennsylvania · Recruiting
Baptist Cancer Center - Memphis
Memphis, Tennessee · Recruiting
University of Wisconsin
Madison, Wisconsin · Not yet recruiting
Hospital Britanico de Buenos Aires
CABA, Argentina · Recruiting
Clinica Adventista Belgrano
CABA, Argentina · Recruiting
Clinica Privada Independencia
Munro, Argentina · Recruiting
Sanatorio Allende S.A.
Nueva Córdoba, Argentina · Recruiting
Sanatorio Parque S.A.
Rosario, Argentina · Recruiting
Prince of Wales Hospital-Randwick-66496
Randwick, New South Wales, Australia · Recruiting
Cancer Research South Australia
Adelaide, South Australia, Australia · Recruiting
Ballarat Regional Integrated Cancer Centre
Ballarat, Victoria, Australia · Recruiting
Hospital Elisabethinen Linz
Linz, Austria · Recruiting
Johannes Kepler University Linz
Linz, Austria · Recruiting
Standort Penzing der Klinik Ottakring
Vienna, Austria · Recruiting
Centre Hospitalier Interrégional Edith Cavell (CHIREC)
Brussels, Belgium · Not yet recruiting
Universitair Ziekenhuis Antwerpen
Edegem, Belgium · Not yet recruiting
Universitair Ziekenhuis Brussel
Jette, Belgium · Not yet recruiting
UZ Leuven
Leuven, Belgium · Not yet recruiting
Hospital de Amor
Barretos, Brazil · Recruiting
Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa Sociedade Simples
Porto Alegre, Brazil · Recruiting
Irmandade da Santa Casa de Misericórdia de Porto Alegre
Porto Alegre - RS, Brazil · Recruiting
Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto
São José do Rio Preto, Brazil · Recruiting
Multiprofile Hospital For Active Treatment-Uni Hospital Ltd.
Panagyurishte, Bulgaria · Not yet recruiting
MHAT Heart and brain
Pleven, Bulgaria · Not yet recruiting
Verspeeten Family Cancer Centre (LHSC)
London, Ontario, Canada · Not yet recruiting
Sault Area Hospital
Sault Ste. Marie, Ontario, Canada · Not yet recruiting
Icegclinic
La Florida, Chile · Recruiting
Showing 40 of 242 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.